'Alzheimer's Drug Hopeful' Adel Withdraws IPO, Fails to Get Valuation Amid Biotech Chill
Remaining listing schedule canceled after book building
Weak stock market and share overhang weigh on offering
"We will develop a new strategy to pursue a listing"
Adel, which is developing a treatment for Alzheimer's disease, has halted its KOSDAQ listing process. Even a company that secured a technology transfer deal worth KRW 1.4 trillion with Sanofi failed to get the valuation it sought in the frozen IPO market. Analysts say institutional investors have begun discounting the future value of biotech companies developing new drugs, as one newly listed stock after another has fallen below its IPO price.
On November 20, Adel disclosed that it had filed a withdrawal notice for its securities registration statement with the Financial Services Commission. The company said it had decided to withdraw after conducting book building and considering various circumstances, including the difficulty of obtaining an appropriate valuation amid recent conditions.
Yoon Seungyong, CEO of Adel, speaks at an IPO briefing held at Hanwha Financial Center in Yeongdeungpo-gu, Seoul, on the 18th. Photo by Park Jeongyeon.
View original imageAdel had planned to offer 2.17 million shares. The indicative price range was KRW 18,000 to KRW 25,000 per share, with the offering expected to raise KRW 39.1 billion to KRW 54.3 billion. At the top of the range, the company's market capitalization would have been KRW 541.5 billion. Institutional book building took place from November 12 to 18. However, many orders reportedly came in below the bottom of the indicative price range, KRW 18,000.
The company said most institutional investors cited market conditions, rather than the company's business, as a concern. An Adel representative said, "Most said they recognized the company's competitiveness but that market conditions are extremely difficult right now." The representative added, "Some also said they were concerned about the large volume of shares that would be available for trading on the first day of listing. Ultimately, most investors withdrew their orders on the final day, making it difficult to proceed."
Recent conditions in the biotech IPO market worked against Adel. According to industry sources, the share prices of four of the five pharmaceutical and biotech companies newly listed on KOSDAQ in the third quarter are below their IPO prices. Nexi, a drug development company that listed on November 12, fell about 40% below its IPO price of KRW 8,000 on its first day of trading. Its share price later dropped to the low KRW 4,000s.
Industry sources say falling share prices of listed biotech companies are also lowering valuations for unlisted biotech companies preparing to go public. Drug developers without products on the market value their companies based on future revenue, including royalties from technology licensing deals. As the market cools, investors are becoming more cautious when assessing the likelihood of future deals and are assigning lower valuations to companies. Adel currently has no products on the market, and the upfront payment it received under its technology transfer agreement with Sanofi last year is its main source of income.
Adel plans to pursue a listing again, but not under the same terms as before. An Adel representative said, "We don't think it would be a good strategy to try again on the same terms solely because the market has recovered. We will develop a new listing strategy going forward."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Adel was founded in 2016 by CEO Yoon Seungyong, a former professor at Asan Medical Center. The company is developing antibodies that selectively target abnormal forms of proteins that cause Alzheimer's disease. In December last year, Adel and Oscotec licensed their jointly developed Alzheimer's disease drug candidate ADEL-Y01 to Sanofi in a deal worth up to $1.04 billion (approximately KRW 1.3917 trillion). Adel raised KRW 49 billion in pre-IPO investment in April this year and passed its preliminary listing review on October 8.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.